利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

77 条记录 (耗时 0.043 秒)

    Methods for generating immune responses employing modified vaccinia of fowlpox viruses
    61.
    发明授权
    Methods for generating immune responses employing modified vaccinia of fowlpox viruses 失效
    使用修复的禽痘病毒痘苗产生免疫应答的方法

    公开(公告)号：US6103244A

    公开(公告)日：2000-08-15

    申请号：US651472

    申请日：1996-05-22

    申请人： Friedrich Dorner ,  Friedrich Scheiflinger ,  Falko Gunter Falkner ,  Michael Pfleiderer

    发明人： Friedrich Dorner ,  Friedrich Scheiflinger ,  Falko Gunter Falkner ,  Michael Pfleiderer

    IPC分类号： C12N7/00 ,  A61K39/275 ,  A61P31/12 ,  A61P37/04 ,  C07K14/16 ,  C07K14/745 ,  C07K14/755 ,  C12N1/00 ,  C12N5/00 ,  C12N7/01 ,  C12N7/08 ,  C12N9/64 ,  C12N9/68 ,  C12N9/74 ,  C12N15/00 ,  C12N15/09 ,  C12N15/64 ,  C12N15/863 ,  A61K39/12 ,  A61K39/21

    CPC分类号： C12N15/86 ,  C07K14/005 ,  C07K14/745 ,  C07K14/755 ,  C12N15/64 ,  C12N9/6429 ,  C12N9/6435 ,  C12N9/644 ,  C12Y304/21005 ,  C12Y304/21007 ,  C12Y304/21022 ,  C12N2710/24043 ,  C12N2710/24143 ,  C12N2740/16222

    摘要： A method is disclosed for producing a modified eukaryotic cytoplasmic DNA virus by direct molecular cloning of a modified DNA molecule comprising a modified cytoplasmic DNA virus genome. The inventive method comprises the steps of (I) modifying under extracellular conditions a DNA molecule comprising a first cytoplasmic DNA virus genome to produce a modified DNA molecule comprising the modified cytoplasmic DNA virus genome; (II) introducing the modified DNA molecule into a first host cell which packages the modified DNA molecule into infectious virions; and (III) recovering from the host cell virions comprised of the modified viral genome. The host cell is infected with a helper virus which is expressed to package the modified viral genome into infectious virions. Examples of packaging a modified poxvirus genome by a helper poxvirus of the same or different genus are described. Also disclosed are novel poxvirus vectors for direct molecular cloning of open reading frames into a restriction enzyme cleavage site that is unique in the vector. In one model poxvirus vector, the open reading frame is transcribed by a promoter located in the vector DNA upstream of a multiple cloning site comprised of several unique cleavage sites.

    摘要翻译： 公开了通过直接分子克隆包含修饰的细胞质DNA病毒基因组的修饰的DNA分子来产生修饰的真核细胞质DNA病毒的方法。 本发明的方法包括以下步骤：（I）在细胞外条件下修饰包含第一细胞质DNA病毒基因组的DNA分子以产生包含修饰的细胞质DNA病毒基因组的修饰的DNA分子; （II）将修饰的DNA分子引入到将修饰的DNA分子包装成感染性病毒粒子的第一宿主细胞中; 和（III）从由修饰的病毒基因组组成的宿主细胞病毒粒子中回收。 宿主细胞感染辅助病毒，其被表达为将经修饰的病毒基因组包装成感染性病毒粒子。 描述了通过相同或不同属的辅助痘病毒包装修饰的痘病毒基因组的实例。 还公开了用于将开放阅读框直接分子克隆到在载体中独特的限制酶切割位点的新型痘病毒载体。 在一个模型痘病毒载体中，开放阅读框架由位于由多个独特的切割位点组成的多克隆位点上游的载体DNA中的启动子转录。

    Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII
    65.
    发明授权
    Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII 有权
    治疗患有出血性疾病的患者的方法，包括对FVIII的A3-C1施用抗体

    公开(公告)号：US08586538B2

    公开(公告)日：2013-11-19

    申请号：US10512907

    申请日：2003-04-28

    申请人： Koenraad Mertens ,  Arend N. Bovenschen ,  Jan Voorberg ,  Manfred Rieger ,  Friedrich Scheiflinger

    发明人： Koenraad Mertens ,  Arend N. Bovenschen ,  Jan Voorberg ,  Manfred Rieger ,  Friedrich Scheiflinger

    IPC分类号： A61K38/36 ,  A61K38/37 ,  A61K39/00

    CPC分类号： C07K14/755 ,  A61K38/00 ,  A61K39/00 ,  C07K14/775 ,  C07K16/36 ,  C07K2317/622 ,  C07K2317/76

    摘要： The present invention concerns the use of peptides derived from and antibodies generated against Factor VIII and the inhibition of Factor VIII interaction with LRP. Furthermore, the present invention concerns a method to inhibit LRP interaction with Factor VIII as well as a method to decrease Factor VIII degradation and/or prolong Factor VIII half-life in a biological fluid and/or a method to treat patients suffering from a blood coagulation disorder, especially Haemophilia A. The present invention also concerns a pharmaceutical composition useful for the decrease of Factor VIII degradation in a biological fluid, the inhibition of Factor VIII interaction with LRP, and/or the prolongation of Factor VIII half-life in a biological fluid for treatment of a blood coagulation disorder, especially Haemophilia A.

    摘要翻译： 本发明涉及使用衍生自针对因子VIII产生的抗体和针对因子VIII与LRP的相互作用的抑制。 此外，本发明涉及抑制与因子VIII的LRP相互作用的方法以及降低生物流体中因子VIII降解和/或延长因子VIII半衰期的方法和/或治疗患有血液的患者的方法 凝血障碍，特别是血友病A.本发明还涉及可用于降低生物流体中因子VIII降解，抑制因子VIII与LRP的相互作用的药物组合物和/或因子VIII半衰期延长 用于治疗凝血障碍的生物流体，特别是血友病。

    Polymer-Von Willebrand Factor-Conjugates
    68.
    发明申请
    Polymer-Von Willebrand Factor-Conjugates 有权
    聚合物Von Willebrand因子 - 缀合物

    公开(公告)号：US20110111455A1

    公开(公告)日：2011-05-12

    申请号：US13007208

    申请日：2011-01-14

    申请人： Friedrich Scheiflinger ,  Peter Turecek ,  Juergen Siekmann

    发明人： Friedrich Scheiflinger ,  Peter Turecek ,  Juergen Siekmann

    IPC分类号： C12P21/02 ,  C07K14/47

    CPC分类号： C07K14/755 ,  A61K47/60 ,  C07K14/775

    摘要： The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.

    摘要翻译： 本发明涉及包含血浆和/或重组血管性血友病因子（VWF）的蛋白质构建体（也称为聚合物-WWF-缀合物），所述VWF结合至少一个生理上可接受的聚合物分子，以及与复合物 在所述蛋白质构建体和至少一种因子VIII（FVIII）蛋白之间。 生理上可接受的聚合物分子可以是例如聚乙二醇（PEG）或聚唾液酸（PSA）。 此外，本发明涉及用于延长具有与FVIII或VWF中的至少一种的功能缺陷或缺陷相关的出血性疾病的哺乳动物的血液中VWF或FVIII的体内半衰期的方法。

    Highly phosphorylated and sulfated recombinant factor IX
    69.
    发明授权
    Highly phosphorylated and sulfated recombinant factor IX 有权
    高度磷酸化和硫酸化重组因子IX

    公开(公告)号：US07575897B2

    公开(公告)日：2009-08-18

    申请号：US12058473

    申请日：2008-03-28

    申请人： Friedrich Scheiflinger ,  Ernst Boehm ,  Michele Himmelspach ,  Olaf Merkel

    发明人： Friedrich Scheiflinger ,  Ernst Boehm ,  Michele Himmelspach ,  Olaf Merkel

    IPC分类号： C12P21/06

    CPC分类号： C12N9/644 ,  A61K38/36 ,  C12Y304/21022

    摘要： The present invention relates to a purified recombinant blood coagulation factor IX (rFIX) preparation, wherein at least 25% of the rFIX in the preparation is fully phosphorylated and sulfated, a cell culture expressing a rFIX resulting in said preparation, a pharmaceutical composition for treating a bleeding disorder comprising said preparation, and a method for treating a bleeding disorder comprising the step of administering said preparation to a patient in need thereof.

    摘要翻译： 本发明涉及纯化的重组凝血因子IX（rFIX）制剂，其中至少25％的制剂中的rFIX被完全磷酸化和硫酸化，表达产生所述制备的rFIX的细胞培养物，用于治疗的药物组合物 包括所述制剂的出血病症和治疗出血性疾病的方法，包括将所述制剂给予需要的患者的步骤。